Alector (NASDAQ:ALEC) Upgraded at Wall Street Zen

Key Points

• Alector has been upgraded from a "sell" rating to a "hold" rating by Wall Street Zen, while Mizuho has raised its rating from "neutral" to "outperform" with a new price target of $3.50.
• Currently, Alector has a consensus price target of $4.17 and is experiencing a 4.2% decline in share price, trading around $2.75.
• Insider trading activity shows a Director sold 14,000 shares at $2.36, leading to a 15.75% decrease in their position, amidst increasing institutional investor interest.

Wall Street Zen upgraded shares of Alector (NASDAQ:ALEC - Free Report) from a sell rating to a hold rating in a report published on Saturday morning.

Separately, Mizuho raised Alector from a "neutral" rating to an "outperform" rating and raised their price target for the company from $2.50 to $3.50 in a report on Monday, July 28th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and two have assigned a Sell rating to the stock. Based on data from MarketBeat, Alector has an average rating of "Hold" and a consensus price target of $4.17.

Alector Stock Performance

Alector stock traded up $0.18 during mid-day trading on Friday, hitting $3.13. 707,331 shares of the company's stock traded hands, compared to its average volume of 1,177,903. The firm has a 50 day simple moving average of $2.16 and a two-hundred day simple moving average of $1.59. Alector has a fifty-two week low of $0.87 and a fifty-two week high of $6.37. The stock has a market cap of $316.79 million, a price-to-earnings ratio of -2.70 and a beta of 0.99. The company has a debt-to-equity ratio of 0.13, a current ratio of 3.78 and a quick ratio of 3.78.

Alector (NASDAQ:ALEC - Get Free Report) last announced its quarterly earnings results on Thursday, August 7th. The company reported ($0.30) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.45) by $0.15. Alector had a negative return on equity of 112.06% and a negative net margin of 142.10%.The business had revenue of $7.87 million during the quarter, compared to the consensus estimate of $2.76 million. Alector has set its FY 2025 guidance at EPS. On average, research analysts expect that Alector will post -1.88 EPS for the current fiscal year.

Insider Transactions at Alector

In other Alector news, Director Paula Hammond sold 14,000 shares of Alector stock in a transaction dated Tuesday, August 26th. The stock was sold at an average price of $2.36, for a total value of $33,040.00. Following the transaction, the director owned 74,909 shares in the company, valued at $176,785.24. The trade was a 15.75% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at this link. Insiders sold a total of 20,910 shares of company stock valued at $49,255 in the last quarter. Insiders own 9.70% of the company's stock.

Institutional Inflows and Outflows

Hedge funds and other institutional investors have recently bought and sold shares of the business. Squarepoint Ops LLC bought a new stake in shares of Alector during the fourth quarter worth about $25,000. Tema Etfs LLC bought a new stake in shares of Alector during the fourth quarter worth about $27,000. FNY Investment Advisers LLC grew its holdings in shares of Alector by 100.0% during the second quarter. FNY Investment Advisers LLC now owns 20,000 shares of the company's stock worth $28,000 after purchasing an additional 10,000 shares during the last quarter. Prudential Financial Inc. bought a new stake in shares of Alector during the second quarter worth about $30,000. Finally, CWM LLC grew its holdings in shares of Alector by 370.7% during the first quarter. CWM LLC now owns 33,643 shares of the company's stock worth $41,000 after purchasing an additional 26,495 shares during the last quarter. Institutional investors own 85.83% of the company's stock.

About Alector

Alector, Inc, a clinical stage biopharmaceutical company, develops therapies for the treatment of neurodegeneration diseases. Its products include AL001, an immune activity in the brain with genetic links to multiple neurodegenerative disorders, which is in Phase III clinical trial for the treatment of frontotemporal dementia, Alzheimer's, Parkinson's, and amyotrophic lateral sclerosis diseases; and AL101 that is in Phase I clinical trial for the treatment of neurodegenerative diseases, including Alzheimer's and Parkinson's diseases.